The Golden Star. Read more.

RXII - RXI Pharmaceuticals Corporation

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ

RXII - RXI Pharmaceuticals Corporation

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ

Fri 19'th Jan 2018

PERIOD 2017-10-20 - 2018-01-19
CHANGE -2.43%
PRICE $4.42





Request Prediction

RXI Pharmaceuticals Corporation Stock Analysis

Technical stock analysis for Fri 19'th Jan 2018

Shorts 4.92% ( 2017-12-29 )
Cash n/a
Loans n/a
Beta 2.10
ROA -271.89
Sell candidate since 2017-12-28 Loss -19.65%

RXI Pharmaceuticals Corporation fell by -2.43% in the last day from $4.53 to $4.42 and has now fallen 3 days in a row. The price has fallen in 7 of the last 10 days and is down by -14.01% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -1 985 shares and in total 17 265 shares bought and sold for approximately $76 311.

Access today's Top 5 Sell Candidates

Learn how to trade RXII stocks


RXI Pharmaceuticals Corporation lies in the lower of a very wide and falling trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at $4.07 will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -14.69% during the next 3 months and, with 90% probability hold a price between $3.47 and $5.50 at the end of this period.

Click here for today's Top 5 Trending Companies


Some negative signals were issued as well, and these may have some influence on the near short-term development. RXI Pharmaceuticals Corporation holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $5.48. On a fall, the stock will find some support from the short-term average at $4.41. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. A sales signal was issued from a pivot top point on Wednesday January 17, 2018, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

The stock currently holds a RSI14 at 26 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Access full RSI 14 and RSI 21 lists

Support & Resistance

RXI Pharmaceuticals Corporation finds support from accumulated volume at $4.41. On the upside the stock meets some resistance just above today's level from accumulated volume at $4.50, $4.69 and $4.69.

The stock is about to test the resistance from accumulated volume at $4.50 and this may cause the stock to take a minor break or get into a more sideways move for a few days.

Support: $4.41 Price: $4.42 Resistance: $4.50


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.29 between high and low, or 6.81%. For the last week the stock has had a daily average volatility of 10.11%.

RXI Pharmaceuticals Corporation is oversold on RSI14 (26). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High


RXI Pharmaceuticals Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Short Sell RXII CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

Access these features

Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder
Ad-free browsing

Become a PRO Now

books of the week

Last donation

Do you find our website useful too?
Help us improve by making a small donation or
Get PRO features